195 related articles for article (PubMed ID: 19106292)
1. Use of the Rad51 promoter for targeted anti-cancer therapy.
Hine CM; Seluanov A; Gorbunova V
Proc Natl Acad Sci U S A; 2008 Dec; 105(52):20810-5. PubMed ID: 19106292
[TBL] [Abstract][Full Text] [Related]
2. Rad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer.
Hine CM; Seluanov A; Gorbunova V
Mol Ther; 2012 Feb; 20(2):347-55. PubMed ID: 22008909
[TBL] [Abstract][Full Text] [Related]
3. Utilization of Rad51C promoter for transcriptional targeting of cancer cells.
Cao Y; Xu Y; Zhang L; Li Z; Jiang Y; Tian X; Seluanov A; Gorbunova V; Mao Z
Oncotarget; 2014 Apr; 5(7):1805-11. PubMed ID: 24742710
[TBL] [Abstract][Full Text] [Related]
4. Use of the XRCC2 promoter for in vivo cancer diagnosis and therapy.
Chen Y; Li Z; Xu Z; Tang H; Guo W; Sun X; Zhang W; Zhang J; Wan X; Jiang Y; Mao Z
Cell Death Dis; 2018 Apr; 9(4):420. PubMed ID: 29549248
[TBL] [Abstract][Full Text] [Related]
5. Regulation of Rad51 promoter.
Hine CM; Li H; Xie L; Mao Z; Seluanov A; Gorbunova V
Cell Cycle; 2014; 13(13):2038-45. PubMed ID: 24781030
[TBL] [Abstract][Full Text] [Related]
6. CtBP1 transactivates RAD51 and confers cisplatin resistance to breast cancer cells.
Deng Y; Guo W; Xu N; Li F; Li J
Mol Carcinog; 2020 May; 59(5):512-519. PubMed ID: 32124501
[TBL] [Abstract][Full Text] [Related]
7. Optimization of a synthetic beta-catenin-dependent promoter for tumor-specific cancer gene therapy.
Lipinski KS; Djeha HA; Gawn J; Cliffe S; Maitland NJ; Palmer DH; Mountain A; Irvine AS; Wrighton CJ
Mol Ther; 2004 Jul; 10(1):150-61. PubMed ID: 15233950
[TBL] [Abstract][Full Text] [Related]
8. MUC1 Promoter-Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer.
Tholey RM; Lal S; Jimbo M; Burkhart RA; Blanco FF; Cozzitorto JA; Eisenberg JD; Jiang W; Iacobuzio-Donahue CA; Witkiewicz AK; Glbert M; Yeo CJ; Brody JR; Sawicki JA; Winter JM
Mol Cancer Res; 2015 Mar; 13(3):439-48. PubMed ID: 25336517
[TBL] [Abstract][Full Text] [Related]
9. [Effect of recombinant adenovirus Ad-DT-A in targeted therapy for malignant cancer cell lines with loss of IGF2 imprinting].
Pan YQ; He BS; Zhu C; Qu LL; Xu XF; Wang SK
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):816-21. PubMed ID: 22335945
[TBL] [Abstract][Full Text] [Related]
10. Heat-induced transcription of diphtheria toxin A or its variants, CRM176 and CRM197: implications for pancreatic cancer gene therapy.
Fogar P; Navaglia F; Basso D; Zambon CF; Moserle L; Indraccolo S; Stranges A; Greco E; Fadi E; Padoan A; Pantano G; Sanzari MC; Pedrazzoli S; Montecucco C; Plebani M
Cancer Gene Ther; 2010 Jan; 17(1):58-68. PubMed ID: 19609296
[TBL] [Abstract][Full Text] [Related]
11. Aberrant Regulation of RAD51 Promotes Resistance of Neoadjuvant Endocrine Therapy in ER-positive Breast Cancer.
Jia Y; Song Y; Dong G; Hao C; Zhao W; Li S; Tong Z
Sci Rep; 2019 Sep; 9(1):12939. PubMed ID: 31506496
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of the promoter region of the human DNA-repair gene Rad51.
Hasselbach L; Haase S; Fischer D; Kolberg HC; Stürzbecher HW
Eur J Gynaecol Oncol; 2005; 26(6):589-98. PubMed ID: 16398215
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy for B-cell lymphoma in a SCID mouse model using an immunoglobulin-regulated diphtheria toxin gene delivered by a novel adenovirus-polylysine conjugate.
Cook DR; Maxwell IH; Glode LM; Maxwell F; Stevens JO; Purner MB; Wagner E; Curiel DT; Curiel TJ
Cancer Biother; 1994; 9(2):131-41. PubMed ID: 7812362
[TBL] [Abstract][Full Text] [Related]
14. Tumor cell kill by c-MYC depletion: role of MYC-regulated genes that control DNA double-strand break repair.
Luoto KR; Meng AX; Wasylishen AR; Zhao H; Coackley CL; Penn LZ; Bristow RG
Cancer Res; 2010 Nov; 70(21):8748-59. PubMed ID: 20940401
[TBL] [Abstract][Full Text] [Related]
15. p62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cells.
Thompson HG; Harris JW; Wold BJ; Lin F; Brody JP
Oncogene; 2003 Apr; 22(15):2322-33. PubMed ID: 12700667
[TBL] [Abstract][Full Text] [Related]
16. Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells.
Collis SJ; Tighe A; Scott SD; Roberts SA; Hendry JH; Margison GP
Nucleic Acids Res; 2001 Apr; 29(7):1534-8. PubMed ID: 11266555
[TBL] [Abstract][Full Text] [Related]
17. A peptide nucleic acid targeting nuclear RAD51 sensitizes multiple myeloma cells to melphalan treatment.
Alagpulinsa DA; Yaccoby S; Ayyadevara S; Shmookler Reis RJ
Cancer Biol Ther; 2015; 16(6):976-86. PubMed ID: 25996477
[TBL] [Abstract][Full Text] [Related]
18. Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51.
Lee JO; Kang MJ; Byun WS; Kim SA; Seo IH; Han JA; Moon JW; Kim JH; Kim SJ; Lee EJ; In Park S; Park SH; Kim HS
Breast Cancer Res; 2019 Oct; 21(1):115. PubMed ID: 31640742
[TBL] [Abstract][Full Text] [Related]
19. Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation.
Hannay JA; Liu J; Zhu QS; Bolshakov SV; Li L; Pisters PW; Lazar AJ; Yu D; Pollock RE; Lev D
Mol Cancer Ther; 2007 May; 6(5):1650-60. PubMed ID: 17513613
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of RAD51 expression is associated with progression of thyroid carcinoma.
Sarwar R; Sheikh AK; Mahjabeen I; Bashir K; Saeed S; Kayani MA
Exp Mol Pathol; 2017 Jun; 102(3):446-454. PubMed ID: 28502582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
